Melanotan I
Also known as: MT-I, Afamelanotide, SCENESSE
Melanocortin Receptor Agonist
Overview
Synthetic analog of α-MSH that selectively targets MC1 receptors for melanin stimulation. FDA-approved as SCENESSE implant for erythropoietic protoporphyria (EPP). Research-grade injectable form enables flexible dosing versus the implant version.
Key benefits
- Precise dosing control with rapid tanning onset
- Flexible home administration unlike implant version
- Visible tanning within 1-2 weeks with UV exposure
- Enhanced photoprotection through increased melanin
- More selective for MC1R than Melanotan II
Mechanism of action
Subcutaneous injection delivers peptide directly into systemic circulation. Selectively activates MC1R receptors to stimulate melanin production. Short half-life of approximately 30 minutes necessitates multiple daily dosing for sustained effect.
Molecular data
- Type
- Synthetic peptide analog
- Half-life
- ~30 minutes
Sequence
α-melanocyte stimulating hormone analog
Indications
What the research community uses this compound for, with self-reported effectiveness.
Skin Health
Medical Applications
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 0.25-0.5mg | 1-2x daily for 1-2 weeks | — |
| — | 0.25-0.5mg | 2-3x weekly | — |
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 0.5mg per spray | 2-3x daily | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Mild nausea
- Facial flushing
- Reduced appetite
- Increased mole/freckle pigmentation
Rare side effects
- Injection site reactions
Monitoring
- Monitor moles regularly via self-examination
- Maintain UV protection despite enhanced tanning
References
Primary literature and clinical-trial data informing this entry.